Brokerages Set Tobira Therapeutics Inc. (NASDAQ:TBRA) PT at $68.63
Shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) have received an average rating of “Buy” from the six ratings firms that are covering the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $68.63.
Several research analysts recently weighed in on TBRA shares. Cantor Fitzgerald downgraded shares of Tobira Therapeutics from a “buy” rating to a “hold” rating and upped their price target for the stock from $19.00 to $42.00 in a research report on Wednesday, September 21st. Zacks Investment Research upgraded shares of Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research report on Friday, July 29th. Cowen and Company restated a “buy” rating and set a $11.00 price target on shares of Tobira Therapeutics in a research report on Wednesday, August 10th. Mizuho restated a “buy” rating and set a $305.00 price target on shares of Tobira Therapeutics in a research report on Thursday, September 22nd. Finally, HC Wainwright restated a “buy” rating and set a $31.00 price target (up previously from $22.00) on shares of Tobira Therapeutics in a research report on Saturday, August 13th.
In other news, major shareholder A/S Novo sold 59,067 shares of the stock in a transaction that occurred on Wednesday, July 13th. The shares were sold at an average price of $12.02, for a total value of $709,985.34. Following the completion of the sale, the insider now owns 1,914,541 shares of the company’s stock, valued at approximately $23,012,782.82. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Pentwater Capital Management L purchased 1,624,200 shares of the company’s stock in a transaction dated Thursday, September 22nd. The stock was purchased at an average cost of $39.04 per share, with a total value of $63,408,768.00. The disclosure for this purchase can be found here. Corporate insiders own 6.20% of the company’s stock.
Several hedge funds have recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. purchased a new stake in Tobira Therapeutics during the second quarter valued at $177,000. Teachers Advisors Inc. boosted its stake in Tobira Therapeutics by 287.1% in the second quarter. Teachers Advisors Inc. now owns 14,484 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 10,742 shares during the period. California State Teachers Retirement System boosted its stake in Tobira Therapeutics by 230.2% in the second quarter. California State Teachers Retirement System now owns 18,578 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 12,951 shares during the period. Bank of New York Mellon Corp purchased a new stake in Tobira Therapeutics during the second quarter valued at $263,000. Finally, Geode Capital Management LLC boosted its stake in Tobira Therapeutics by 2.5% in the first quarter. Geode Capital Management LLC now owns 32,223 shares of the biopharmaceutical company’s stock valued at $263,000 after buying an additional 799 shares during the period. 62.02% of the stock is owned by institutional investors and hedge funds.
Shares of Tobira Therapeutics (NASDAQ:TBRA) opened at 39.95 on Friday. Tobira Therapeutics has a 52 week low of $3.76 and a 52 week high of $41.39. The firm has a 50-day moving average of $10.65 and a 200 day moving average of $9.40. The company’s market cap is $751.90 million.
Tobira Therapeutics (NASDAQ:TBRA) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.08. The company had revenue of $1.06 million for the quarter. Equities analysts expect that Tobira Therapeutics will post ($2.65) EPS for the current fiscal year.
About Tobira Therapeutics
Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.
Receive News & Stock Ratings for Tobira Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Therapeutics Inc. and related stocks with our FREE daily email newsletter.